All AbMole products are for research use only, cannot be used for human consumption.
Tyrphostin 9 (Tyrphostin A9) is a potent PDGFR inhibitor with IC50 of 0.5 μM, it is also a potent inducer of mitochondrial fission. Tyrphostin 9 (Tyrphostin A9) is firstly designed as an EGFR inhibitor with IC50 of 460 μM.
| Molecular Weight | 282.38 |
| Formula | C18H22N2O |
| CAS Number | 10537-47-0 |
| Solubility (25°C) | DMSO 40 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Amanda Chow, et al. Dasatinib inhibits peripapillary scleral myofibroblast differentiation
[3] Lyndsey F Meyer, et al. Development and validation of an LC-MS/MS method for tyrphostin A9
[5] Alberto Camacho, et al. Tyrphostin AG17 inhibits adipocyte differentiation in vivo and in vitro
| Related VEGFR/PDGFR Products |
|---|
| ABT-869
ABT-869 (Linifanib) is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of VEGFR and PDGFR. |
| Tivozanib (AV-951)
Tivozanib (AV-951) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively. |
| Axitinib
Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit. |
| Regorafenib
Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively. |
| Nintedanib
Nintedanib (BIBF1120) is a novel, potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
